ADVISORY BOARD

Kevin Wasserstein specializes in investing and building medical device companies at Versant. His work with entrepreneurs spans the earliest seed or concept stage of development through the entire life cycle of the company. Kevin has more than eighteen years of venture capital and operating experience in medical device and high technology companies, and currently serves, or has served, in board or advisory roles with companies which include: Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cardiac Concepts, LipoSonix (acquired: Medicis), Lutonix, Microfabrica, NeoGuide Systems (acquired: Intuitive Surgical), Rox Medical, Second Sight Medical, St. Francis Medical (acquired: Kyphon) and The Innovation Factory. In addition, he serves as a member of AdvaMed’s National Venture Capital Advisory Board, and MDMA’s Venture Capital Advisory Group. Before joining Versant in 2002, Kevin held a variety of marketing and business development roles at Guidant Corporation. Most recently he served as head of marketing in Guidant's Cardiac Surgery Group, where he led the group’s product/market development and launch initiatives. In Guidant's Peripheral and Carotid Group, Kevin developed and launched several first-generation stent and embolic protection devices while leading the carotid stent program’s marketing activities. Previously, in Guidant's Compass Business Development Group, Kevin’s responsibilities included acquisition, licensing and investment with both private and public medical device companies, and corporate strategy. His operational experience also includes business development at Heartstream, and engineering design and engineering management at Hughes Aircraft Company.

Kevin holds both Bachelor’s and Master's degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.

Michael Berman is a Medical Device Entrepreneur working with a select group of high potential development and early commercial stage companies. From 1995-2000 Mr. Berman was President of Boston Scientific/Scimed. From 1997 to 2000 he was a member of Boston Scientific’s Executive Committee.

• Mr. Berman is currently working with the following companies:

• Aetherworks I and II, Co-founder and Member of the Board of Directors since 2003. A Medical Device incubator.

• Apnex, Co-founder and Chairman of the Board. A company spun out of Prospex developing an active implant for the treatment of Obstructive Sleep Apnea.

• Benechill, Co-founder and member of the Board of Directors since 2004. A company developing a Therapeutic Hypothermia system for the treatment of Cardiac Arrest.

• BridgePoint Medical, Co-founder and Chairman of the Board. A company spun out of Prospex developing technology to Coronary Chronic Total Occlusions.

• Conceptx, Co-founder and member of the Board of Directors since 2007. A Medical Device Accelerator.

• Lutonix, member of the Board of Directors since 2007.

• PharmaCentra, member of the Board of Directors since 2005.

• Data Sciences International member of the Board of Directors since 2001. The leading company in the field of wireless implantable diagnostic monitors for the Animal Research market.

• UltraShape, Chairman of the Board of Directors since 2005. The leading company developing and selling non-invasive body contouring products.

Mr. Berman has previously served on the boards of Coaxia, Curon, Myocor and TopSpin. In addition, in 2000, Mr. Berman co-founded Velocimed, and served as a board member until the company was sold to St. Jude Medical in April 2005 for $82.5 million upfront plus contingent payments. Since 2000, Mr. Berman has served on the boards of companies that have collectively raised over $350 million.

Mr. Berman joined Scimed in November of 1986. In January of 1987 Scimed launched it’s first balloon angioplasty catheter in the USA. Mr. Berman started as Scimed’s first Product Manager working on the development and introduction of PTCA catheters. As Director of Marketing from 1988-1989 and Vice President of Marketing from 1990-1993, Mr. Berman led all of Scimed’s interventional cardiology marketing efforts. He developed a partnership with the product development organization, guided the R&D portfolio and oversaw all product definition activities. During his leadership of Marketing, Scimed introduced numerous key products that established the company as an emerging leader in Interventional Cardiology. Key products included the Skinny, the first low profile over the wire catheter, the ACE fixed wire catheter, and the TriGuide – Scimed’s first guide catheter. Scimed’s Interventional Cardiology Revenue grew from zero in 1986 to over $100 million in 1990.

Named Vice President of Marketing and Business Manager of New Modalities in 1993 Mr. Berman led Scimed’s early efforts to develop new technologies to improve the treatment of Coronary Disease. These technologies included Intracoronary Stents, Site Specific Drug Delivery, Arterial Access Site Sealing, and Expandable Rotational Atherectomy.

As Vice President of Sales and Marketing in 1994, Mr. Berman opened new doors for Scimed business in the United States, Europe and Asia, and helped to shape the Scimed sales force into a collaborative partner with interventional cardiologists worldwide. He has advanced many ideas and people within the organization.

In 1995, after Scimed’s merger with Boston Scientific Mr. Berman was appointed President of Scimed. Under his leadership Boston Scientific Scimed successfully acquired and integrated Cardiovascular Imaging Systems ($10 million revenue), Heart Technology ($60 million revenue) and Schneider Cardiology ($200 million revenue). The aggregate purchase price of these acquired companies was nearly $3 billion. During this same time period Scimed successfully partnered with Medinol Ltd and entered the intracoronary stent business growing to $600 million in Revenue in 1999.

As President of Scimed, Mr. Berman expanded the company’s leadership in the interventional cardiology market. Under his leadership, the company increased worldwide sales from $300 million to $1.5 billion, fully integrated four acquired interventional cardiology businesses, invested more than $250 million in research and technology, and introduced more than 40 new products. As President of Scimed, Mr. Berman provided leadership and management for more than 4000 employees in four locations.

In 1997 Mr. Berman was appointed to the Boston Scientific Executive Committee, became a Senior Vice President of BSC, Group President of the Cardiology Businesses and assumed the additional responsibility for the management of EPT a division with $60 million in revenue serving Electrophysiologists diagnosing and treating Cardiac Arrhythmias.

Prior to joining Scimed, Mr. Berman worked in marketing for Marietta Corporation from 1985-1986 and in Baxter Corporation’s Israel facility from 1981-1984. Mr. Beman is fluent in Hebrew. He graduated from Cornell University in 1979 with a BS in Industrial and Labor Relations and later in 1986 with an MBA.

Mr. Berman has been involved with a number of trade and business associations including the American Israel Chamber of Commerce, Memorial Blood Centers Business Advisory Group, and the University of Minnesota Institute of BioMedical Engineering. In addition he served as the Chairman of the Minneapolis Jewish Community Foundation from 2002-2005, has served on the board of the Minneapolis Jewish Day School, was a member of the American Heart Assoc. Executive Leadership team in 2006-7, and was the Corporate Chair of the Juvenile Diabetes Association 1997 Walkathon.

He and his wife Judith, a professor of Molecular Genetics at the University of Minnesota, have two sons.

Josh Baltzell is a Managing Director at Split Rock Partners and has been with the firm since its inception in June 2004. Split Rock Partners is a venture firm focused on investments in health care, software and internet enabled services. From 2002 to 2004, Mr. Baltzell was with St. Paul Venture Capital. Prior to joining St. Paul Venture Capital, Mr. Baltzell was an investment banker at Piper Jaffray, where he focused primarily on mergers and acquisitions in the medical device sector. Mr. Baltzell also held various marketing and business development positions with SCIMED/Boston Scientific.

Mr. Baltzell holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota's Carlson School of Management.

Chad Cornell is Vice President of Corporate Development for Medtronic, Inc. Chad has responsibility for supporting Medtronic's CardioVascular business unit (vascular therapies and cardiac surgery therapies), as well as other strategic initiatives within Medtronic. Chad works in partnership with executive and business unit management in evaluating and executing mergers and acquisitions, strategic alliances, joint ventures, minority investments, technology licenses, divestitures and other strategic transactions. Chad also assists in Medtronic's strategic planning process.

Prior to joining Corporate Development, Chad was Legal Counsel - M&A, responsible for advising Corporate Development on strategic transactions across Medtronic. Chad began his career with Medtronic in 2003. Prior to joining Medtronic, Chad spent approximately five years as an associate attorney at Sidley & Austin in Chicago, Illinois working on mergers and acquisitions and securities offerings.

Chad received his undergraduate degree in Accounting from Marquette University and a Juris Doctorate from the University of Pennsylvania. Chad has also successfully completed Certified Public Accountant and Chartered Financial Analyst examinations.

Mark E. DuVal, JD is President of DuVal & Associates, where his firm counsels both mature and venture-backed pharmaceutical, medical device, and biotech companies in the United States and Europe. Their firm also works extensively with combination product submissions to FDA. The DuVal law firm regularly advises clients in all areas of FDA law and regulation, from product pre-market submissions, clinical trials, inspections and recalls to reimbursement and post-marketing responsibilities. He specializes in counseling medical device and pharmaceutical companies in the development and implementation of strategic and tactical sales and marketing plans that are appropriately aggressive, yet compliant, with FDA’s advertising and promotional regulations, the Anti-kickback Statute and the False Claims Act. The firm establishes and then trains and audits sales and marketing compliance programs.

Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical and diagnostics investments. He is a board member of Cardiac Dimensions and Gynesonics. Dr. Fisher also is actively involved in InterWest's investments in Integrated Diagnostics and Invuity.

Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in three new disease areas for Remicade.

Dr. Fisher received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.

Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering, extensive operating experience, and industry connections to select and nurture outstanding companies. Jan has been a member of the board of directors of Arboretum portfolio companies including HandyLab (acquired by Becton, Dickinson and Company), NXThera, Uptake Medical, and VasoNova. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation.

Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Sami Hamadé joined Aberdare as a Partner in 2006. Prior to Aberdare, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant's venture capital and M&A activities. Additionally, Sami led the West Coast Business Development unit which was composed of business development groups from Vascular Intervention, Cardiac Surgery and Endovascular Solutions divisions. Previous to this, Sami played founding roles in the launch and development of significant businesses for Guidant including coronary stents, carotid and peripheral systems. Sami began his career in medical devices at Advanced Cardiovascular Systems.

Sami has been active in the medical device field for the last 19 years. He holds a Bachelors degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.

Bill joined Osage University Partners in 2012. He previously served as a Partner at Three Arch Partners, a venture capital firm with over $1 billion under management. During Bill's twelve years at Three Arch, he focused on medical device, biotechnology, and healthcare service investing. Bill led investments in and served as a director of nearly twenty healthcare companies, a number of which had their origin as university spinouts. He most recently served on the boards of Cameron Health, Baxano, Voyage Medical, Nevro Corporation, APT Pharmaceuticals, and Centerre Healthcare. Prior to entering venture capital in 1999, Bill spent a decade as an interventional radiologist, working with promising new imaging technologies, medical devices, and minimally invasive surgical procedures. Bill holds an MD from Harvard Medical School, an MBA from UC Berkeley, and a BS in Biology and Chemistry from Tufts University. Bill is a CFA charterholder.

David Milne joined SVLS in 2005. David has over 21 years of operating experience in leading therapeutic and diagnostic medical technology corporations. David currently sits on the board of directors for, AqueSys, CardioMind, EBR, Entellus, Novalign, ReShape, Sadra, Spinal Kinetics, and TransEnterix. He is also on the boards of Mindframe and Altura Interventional which reside in the incubator medical technology incubator Intersect Partners.

From 1999, until joining SVLS, he held the position of Vice President of Corporate Business Development at Boston Scientific Corporation and was responsible for over 50 transactions totaling nearly $2 billion in acquisitions, equity investments and development partnerships. Prior responsibilities included executive level positions in marketing, Corporate Planning, and Sales with Boston Scientific, Becton Dickinson and Parker Laboratories. David holds an MBA from New York University and a BS in Biochemistry from Rutgers University.

J.P. Peltier is a managing director and member of the Piper Jaffray health care investment banking team. Peltier has 13 years of investment banking experience at Piper Jaffray focused exclusively on the medical technology sector. Peltier provides medical technology clients with a full range of investment banking services from equity and debt financing to mergers and acquisitions advisory.

Peltier’s prior experience includes five years at HomeServices of America, a Berkshire Hathaway subsidiary, where he served in a M&A advisory role and led the mortgage banking division.

Peltier graduated from the University of St. Thomas and received a Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University.

Dan Sheehan manages the activities of Covidien Ventures. Dan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies. His background includes both venture capital investing and operating company management roles in the healthcare sector. Most recently, Dan was a General Partner with Affinity Capital Management, a healthcare oriented venture capital firm in Minneapolis. He has also managed the business development and strategic marketing efforts for Steris Corporation, a provider of infection prevention and surgical support products for the healthcare and life sciences sectors. He has been a member of the Board of Directors of many portfolio companies. He is a graduate of Fordham University and Columbia Business School.

Mark is an assurance partner and has 19 years of experience with PwC.  Mark is a partner in the PwC Minneapolis office.  From July 2008 through June 2011, Mark was on international secondment at the PwC Seoul, Korea office.  While in Seoul, a significant amount of Mark's time was dedicated to serving Samsung Electronics.  In addition, Mark served US-based clients with investments and operations in Korea.  He has extensive experience in helping large, multinational companies meet the compliance requirements of securities offerings, mergers and acquisitions, SEC reporting, and US GAAP and IFRS requirements. 

Mark has served on several public registrants during his career. Mark has focused on clients in the technology industry - including medical technology/device companies.  He has assisted clients in initial public offerings and other equity and debt filings. He has assisted with the registration of over $2 billion in equity and debt securities since 2004. He has been involved with the resolution of numerous SEC reporting issues.  During 2007, Mark received the PwC Chairman's Award for outstanding client service.

Mr. Silverstein is a General Partner of OrbiMed, the world’s largest asset management firm solely focused in healthcare with roughly $6 billion in assets under management.  OrbiMed manages over a dozen different hedge, venture capital, royalty and mutual funds.  OrbiMed has 75 employees throughout its 5 offices around the globe: New York, San Francisco, Mumbai, Shanghai and Tel Aviv.  Mr. Silverstein joined OrbiMed in 1998 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a Director of Life Sciences in the Investment Banking Department at Sumitomo Bank.  Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.  Currently, Mr. Silverstein is the Chairman of Cerapedics and SuperDimension and a board member of Relypsa, Glaukos, DFine, Arteaus, and Roka Biosciences.  Mr. Silverstein was formerly a chairman, director or observer of Enobia (sold to ALXN), Nxstage Medical (NXTM), Insulet Corporation (PODD),  LifeCell (sold to KCI), Given Imaging (GIVN), Cerexa (sold to FRX), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir (AVNR), Orthovita (VITA), Auxillium (AUXL), Bioenvision (sold to GENZ), Adiana (sold to HOLX), and Adolor (ADLR).

Kathy joined Thomas, McNerney & Partners from Piper Jaffray, where she was a health care analyst focused on medical technology companies. While at Piper, Kathy covered over 20 companies in the medical device, medical supply and diagnostic areas. Her background also includes experience in new product development at Solvay, S.A. (in a division that is now part of Wyeth). Projects at Solvay included the development of vaccines for the prevention of viral infections. Kathy was also a Senior Scientist in molecular biology at the University of Minnesota, where she worked on the development of molecular biology based assays for the detection of infectious agents. Kathy is currently a board member of CAS Medical Systems, Inc. and VertiFlex, Inc. She is also a member of the Executive Leadership Team for the American Heart Association's Go Red for Women campaign. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.

Dale retired from Medtronic in 2006 after 24 years. Most recently he served as V.P. of CRDM Venture Programs. Prior to this he served as V.P./G.M. of the CRDM Therapy Delivery business. Before Medtronic, he held management and sales positions at Litton Microwave and Burroughs Corporation and managed a clean technology start-up company.

Today, he serves as the President and CEO for LifeScience Alley and The BioBusiness Alliance of Minnesota. Dale is currently a member of several industrial advisory and governance boards for different universities and companies. In 1988, he was a recipient of the Medtronic Star of Excellence Award, and in 1997 received the Wallin Leadership Award. In 2002, Dale was recognized as the outstanding graduate of the year by the engineering department of St. Cloud State University. In 2007, he was honored by Twin Cites Business Magazine and was the recipient of the Bioscience Success Story Award. In 2010, Twin Cities Business Magazine selected Dale as one of 200 "Minnesotans You Should Know." He currently has eleven patents in medical device technology with more pending.

Dale received his M.S. in Manufacturing Systems Engineering from the University of St. Thomas in 1994, and his B.S. in Engineering and Technology from St. Cloud State University in 1978.